P. Coursaget

P. Coursaget, H. Chaussade, A. Touzé, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal.

B. Yvonnet, P. Coursaget, M. Chabaud, 1993, British Journal of Cancer.

LACK OF ANTI-HBc IgM IN NEONATES WITH HBsAg CARRIER MOTHERS ARGUES AGAINST TRANSPLACENTAL TRANSMISSION OF HEPATITIS B VIRUS INFECTION

B. Yvonnet, P. Coursaget, A. Goudeau, 1983, The Lancet.

Prevention of hepatitis B virus infection in children born to HBsAg positive/HBeAg positive mothers. Preliminary results of active and passive-active immunization.

P. Coursaget, S. Yeh, A. Goudeau, 1983, Developments in biological standardization.

Nasal Immunization of Mice with Human Papillomavirus Type 16 (HPV-16) Virus-Like Particles or with the HPV-16 L1 Gene Elicits Specific Cytotoxic T Lymphocytes in Vaginal Draining Lymph Nodes

P. Coursaget, C. Dupuy, A. Touzé, 1999, Journal of Virology.

Human Papillomavirus Infection in Women with Cervical Cancer but without Cytological Abnormalities in the Preceding Years

P. Coursaget, N. Muñoz, M. Chabaud, 1994 .

Detection by PCR of human papillomavirus genotypes in cervical lesions of Senegalese women

A. S. Diallo, P. Coursaget, D. Leboulleux, 1996, Journal of medical virology.

NON-A, NON-B HEPATITIS IN BURN PATIENTS

P. Coursaget, P. Levesque, J. Baudet, 1981, The Lancet.

Simultaneous injection of plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines.

P. Coursaget, P. Saliou, B. Fritzell, 1995, Vaccine.

Scheduling of revaccination against hepatitis B virus

N. Day, C. C. Wang, B. Yvonnet, 1991, The Lancet.

Hepatitis B vaccine in infants from an endemic area: Long‐term anti‐HBs persistence and revaccination

B. Yvonnet, P. Coursaget, J. Chiron, 1987, Journal of medical virology.

Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal.

P. Coursaget, R. Gupta, M. Huet, 1991, Vaccine.

Hepatitis B infection in alcoholic liver disease and primary hepatocellular carcinoma in France.

P. Coursaget, A. Goudeau, P. Bougnoux, 1981, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.

EFFICACY OF HEPATITIS B VACCINE IN PREVENTION OF EARLY HBsAg CARRIER STATE IN CHILDREN Controlled Trial in an Endemic Area (Senegal)

P. Coursaget, A. Goudeau, J. Chiron, 1981, The Lancet.

Screening of human papillomavirus infection in women with systemic sclerosis.

P. Coursaget, R. Ramanah, A. Touzé, 2014, Clinical and experimental rheumatology.

Outbreak of enterically-transmitted hepatitis due to hepatitis A and hepatitis E viruses.

P. Coursaget, R. Bercion, Y. Buisson, 1998, Journal of hepatology.

Incidence of hepatitis C virus infection in burn patients: detection of anti-C100, anti-C33c and anti-Core antibodies.

P. Coursaget, P. le Cann, B. Simpson, 1991, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Prevalence of hepatitis C virus infection in Africa: anti-HCV antibodies in the general population and in patients suffering from cirrhosis or primary liver cancer.

B. Yvonnet, P. Coursaget, J. Chiron, 1990, Research in virology.

Automated complement fixation test for the detection of antibodies against the core of hepatitis B virus (HBc).

P. Coursaget, A. Goudeau, I. Millman, 1976, Journal of immunological methods.

HPV vaccines for cervical neoplasia

P. Coursaget, N. Muñoz, L. Crawford, 1995, The Lancet.

Etiology of acute sporadic hepatitis in adults in Senegal and Tunisia.

P. Coursaget, D. Leboulleux, M. Ndao, 1995, Scandinavian journal of infectious diseases.

Serology for human papillomavirus.

P. Coursaget, 2003, Salud publica de Mexico.

Hepatitis B e antigen and alpha-ftoprotein in black african people suffering from liver cirrhosis

B. Yvonnet, P. Coursaget, A. Goudeau, 1982 .

Epidemiological and serological study of hepatitis A virus outbreaks in France: a comparison between immunoadherence and radioimmunoassay

P. Coursaget, P. Hibon, G. Lelord, 1981, Journal of Hygiene.

Hepatitis a diagnosis in man: radioimmunoassay for hepatitis a antigen detection in faeces

P. Coursaget, P. Hibon, P. Maupas, 1980, Journal of medical virology.

Serologic response in human hepatitis A: Detection of antibody by radioimmunoassay and immune adherence hemagglutination

P. Coursaget, L. Barker, E. Tabor, 1979, Journal of medical virology.

Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen

B. Yvonnet, P. Coursaget, J. Chiron, 1986, Infection and immunity.

Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses

P. Coursaget, N. Christensen, A. Touzé, 2002, Journal of Virology.

HBsAg-negative chronic active hepatitis related to hepatitis B virus

P. Coursaget, A. Goudeau, J. Benhamou, 1978, Medical Microbiology and Immunology.

Somatostatin Receptors 2A and 5 Are Expressed in Merkel Cell Carcinoma with No Association with Disease Severity

P. Coursaget, F. Aubin, G. Lorette, 2015, Neuroendocrinology.

Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.

P. Coursaget, C. Meijer, J. Walboomers, 1999, The Journal of general virology.

Detection of hepatitis B virus DNA by polymerase chain reaction in HBsAg negative Senegalese patients suffering from cirrhosis or primary liver cancer.

P. Coursaget, D. Leboulleux, P. le Cann, 1991, FEMS microbiology letters.

Antibodies to human T-cell leukemia virus (HTLV-1) in non human primates from Senegal.

B. Yvonnet, P. Coursaget, J. Chiron, 1985, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Hepatitis B surface antigen (HBsAg) inactivation and angiotensin‐converting enzyme (ACE) inhibition in vitro by Combretum glutinosum perr. (Combretaceae) extract

P. Coursaget, J. Levesque, J. Pousset, 1993 .

Detection of antibodies to L1, L2, and E4 proteins of human papillomavirus types 6, 11, and 16 by ELISA using synthetic peptides

P. Coursaget, D. Leboulleux, M. Chabaud, 1995, Journal of medical virology.

Production of human papillomavirus type 45 virus-like particles in insect cells using a recombinant baculovirus.

P. Coursaget, C. Dupuy, A. Touzé, 1996, FEMS microbiology letters.

Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor.

P. Coursaget, A. Touzé, L. Bousarghin, 2003, The Journal of general virology.

Twelve-year follow-up study of hepatitis B immunization of Senegalese infants.

B. Yvonnet, P. Coursaget, D. Leboulleux, 1994, Journal of hepatology.

Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL49 (VP22) and UL48 (VP16) genes: high-level expression and characterization of MDV-1 VP22 and VP16.

P. Coursaget, F. Dorange, J. Vautherot, 2000, The Journal of general virology.

Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic.

J. M. Seguí-Simarro, P. Coursaget, P. Corral-Martínez, 2008, Plant biotechnology journal.

Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope.

P. Coursaget, J. Sadeyen, P. Sizaret, 2003, Virology.

Human papillomavirus vaccines.

P. Coursaget, F. Breitburd, Pierre Coursaget, 1999, Seminars in cancer biology.

Detection of Human Papillomavirus Type 31-Neutralizing Antibodies from Naturally Infected Patients by an Assay Based on Intracellular Assembly of Luciferase-Expressing Pseudovirions

P. Coursaget, S. de Sanjosé, F. Bosch, 2007, Clinical and Vaccine Immunology.

Detection of Human Papillomavirus Type 31-Neutralizing Antibodies from Naturally Infected Patients by an Assay Based on Intracellular Assembly of Luciferase-Expressing Pseudovirions (cid:1)

P. Coursaget, S. Sanjosé, F. X. Bosch, 2007 .

Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type‐specific neutralizing antibodies and cross‐reactive antibodies

P. Coursaget, J. Sadeyen, P. Sizaret, 2005, Journal of medical virology.

Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity

B. Yvonnet, P. Coursaget, A. Touzé, 2004, Journal of medical virology.

Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.

P. Coursaget, P. Sizaret, A. Touzé, 2008, Vaccine.

The nine C-terminal amino acids of the major capsid protein of the human papillomavirus type 16 are essential for DNA binding and gene transfer capacity.

P. Coursaget, P. Sizaret, C. Dupuy, 2000, FEMS microbiology letters.

Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells.

P. Coursaget, J. Benoit, A. Griveau, 2013, International journal of pharmaceutics.

Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications

P. Coursaget, M. Maurel, T. Moreau, 2009, Protein science : a publication of the Protein Society.

Detection of Neutralizing Antibodies against Human Papillomaviruses (HPV) by Inhibition of Gene Transfer Mediated by HPV Pseudovirions

P. Coursaget, P. Sizaret, M. Bravo, 2002, Journal of Clinical Microbiology.

Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31

P. Coursaget, C. Clavel, A. Touzé, 2006, Archives of Virology.

Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies

P. Coursaget, Nicolas Combelas, A. Touzé, 2010, Journal of Translational Medicine.

IMMUNISATION AGAINST HEPATITIS B IN MAN

P. Coursaget, P. Bagros, A. Goudeau, 1976, The Lancet.

Detection of antibodies to hepatitis E virus in patients with autoimmune chronic active hepatitis and primary biliary cirrhosis.

P. Coursaget, M. Tong, P. le Cann, 1997, Scandinavian journal of gastroenterology.

Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes

P. Coursaget, I. Mushahwar, S. Locarnini, 2004, Intervirology.

Persistence of circulating complexes between HBsAg and immunoglobulin M in sera of hepatitis B surface antigen positive patients suffering from liver cirrhosis or primary liver cancer.

B. Yvonnet, P. Coursaget, S. Mboup, 1986, Cancer research.

Non-a,non-b hepatitis virus

P. Coursaget, P. Maupas, 1985 .

B. Yvonnet, P. Coursaget, J. Chiron, 1987, Journal of medical virology.

Hepatitis B surface antigen reactivity in man due to a new variant of hepatitis B virus.

B. Yvonnet, P. Coursaget, J. Chiron, 1990, Vaccine.

Diagnostic Problems Caused by HBsAg Mutants – A Consensus Report of an Expert Meeting

P. Coursaget, Yoshiyuki Suzuki, O. Yokosuka, 2004, Intervirology.

Epidemiology of primary hepatocellular carcinoma in Senegal.

P. Coursaget, A. Goudeau, J. Chiron, 1981, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.

Detection of hepatitis B virus DNA by polymerase chain reaction in vaccinated and non-vaccinated Senegalese children.

P. Coursaget, D. Leboulleux, A. Coll-Seck, 1993, Archives of virology. Supplementum.

IMMUNE RESPONSE IN NEONATES TO HEPATITIS B VACCINE

B. Yvonnet, P. Coursaget, A. Goudeau, 1982, The Lancet.

Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal.

P. Coursaget, A. Goudeau, J. Chiron, 1981, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.

SEVEN-YEAR STUDY OF HEPATITIS B VACCINE EFFICACY IN INFANTS FROM AN ENDEMIC AREA (SENEGAL)

B. Yvonnet, P. Coursaget, J. Chiron, 1986, The Lancet.

SIMULTANEOUS ADMINISTRATION OF HEPATITIS B AND DIPHTHERIA/TETANUS/POLIO VACCINES

B. Yvonnet, P. Coursaget, J. Chiron, 1984, The Lancet.

Familial clustering of hepatitis B virus infections and prevention of perinatal transmission by immunization with a reduced number of doses in an area of intermediate endemicity (Tunisia).

P. Coursaget, B. Fritzell, N. Boukhris, 1994, Vaccine.

High Hepatitis E Virus Seroprevalence in Forestry Workers and in Wild Boars in France

P. Coursaget, M. Tognon, H. Chaussade, 2012, Journal of Clinical Microbiology.

Baculovirus Expression of Chimeric Hepatitis B Virus Core Particles with Hepatitis E Virus Epitopes and Their Use in a Hepatitis E Immunoassay

P. Coursaget, Y. Buisson, A. Touzé, 1999, Journal of Clinical Microbiology.

[The epidemiology of hepatitis B in Tunisia].

P. Coursaget, Y. Gharbi, N. el Goulli, 1988, Archives de l'Institut Pasteur de Tunis.

Role of hepatitis E virus in sporadic cases of acute and fulminant hepatitis in an endemic area (Chad).

P. Coursaget, Y. Buisson, R. Roué, 1998, The American journal of tropical medicine and hygiene.

Anti-pre-S2 antibodies in natural hepatitis B virus infection and after immunization.

B. Yvonnet, P. Coursaget, P. Saliou, 1988, Vaccine.

Hepatitis b virus antigens in human primary hepatocellular carcinoma tissues

P. Coursaget, A. Goudeau, J. Chiron, 1979, International journal of cancer.

Incidence and significance of hepatitis B e antigen and antibody in postnecrotic cirrhosis and primary hepatocellular carcinoma

P. Coursaget, A. Goudeau, J. Drucker, 1978, Journal of clinical microbiology.

Hepatitis B virus DNA in primary hepatocellular carcinoma tissue

P. Coursaget, J. Summers, A. Goudeau, 1978, Journal of medical virology.

HEPATITIS B VACCINE WITH AND WITHOUT POLYMERISED ALBUMIN RECEPTORS

P. Coursaget, J. Chiron, P. Adamowicz, 1985, The Lancet.

IMMUNE RESPONSES TO HEPATITIS B VACCINE

P. Coursaget, A. Goudeau, C. Kattamis, 1981, The Lancet.

Hepatitis B vaccine: further studies in children with previously acquired hepatitis B surface antigenemia

B. Yvonnet, P. Coursaget, A. Goudeau, 1983, Infection and immunity.

Active immunization against hepatitis B in an area of high endemicity. Part II: Prevention of early infection of the child.

P. Coursaget, A. Goudeau, J. Chiron, 1981, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.

Mapping of linear B-cell epitopes of hepatitis B surface antigen.

P. Coursaget, P. le Cann, C. Bourdil, 1991, Research in virology.

HEPATITIS A VIRUS IN PRIMATES OUTSIDE CAPTIVITY

P. Coursaget, D. Burke, L. Ferrara, 1981, The Lancet.

DNA-containing and empty hepatitis B virus core particles bind similarly to envelope protein domains.

P. Coursaget, C. Hourioux, P. Roingeard, 2000, The Journal of general virology.

Evaluation of the immune response to human papillomavirus types 16, 18, 31, 45 and 58 in a group of Colombian women vaccinated with the quadrivalent vaccine

P. Coursaget, A. Touzé, M. Molano, 2013 .

Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus‐like particles in colombian women with invasive cervical cancer

P. Coursaget, M. Bravo, A. Touzé, 2002, International journal of cancer.

Large scale purification of hepatitis B surface antigen (HBsAg).

P. Coursaget, A. Goudeau, F. Barin, 1978, Annals of Microbiology.

Merkel cell polyomavirus infection occurs during early childhood and is transmitted between siblings.

P. Coursaget, D. Trégouët, L. Abel, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome.

P. Coursaget, F. Aubin, F. Rozenberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of interferon-alpha in two patients with Merkel cell carcinoma positive for Merkel cell polyomavirus

P. Coursaget, F. Aubin, A. Touzé, 2011, Acta oncologica.

Age-Specific Seroprevalences of Merkel Cell Polyomavirus, Human Polyomaviruses 6, 7, and 9, and Trichodysplasia Spinulosa-Associated Polyomavirus

P. Coursaget, M. Tognon, A. Touzé, 2013, Clinical and Vaccine Immunology.

Trichodysplasia Spinulosa Polyomavirus Infection Occurs during Early Childhood with Intrafamilial Transmission, Especially from Mother to Child.

P. Coursaget, L. Abel, V. Pedergnana, 2017, The Journal of investigative dermatology.

Molecular Epidemiology of Merkel Cell Polyomavirus: Evidence for Geographically Related Variant Genotypes

P. Coursaget, P. Afonso, N. Berthet, 2014, Journal of Clinical Microbiology.

Prevalence of human papillomavirus infection in women in Busan, South Korea

P. Coursaget, S. Franceschi, N. Muñoz, 2003, International journal of cancer.

Serological Cross-Reactivity between Merkel Cell Polyomavirus and Two Closely Related Chimpanzee Polyomaviruses

P. Coursaget, M. Tognon, A. Touzé, 2014, PloS one.

Seroprevalence and Cross-reactivity of Human Polyomavirus 9

P. Coursaget, M. Tognon, A. Touzé, 2012, Emerging infectious diseases.

Antibodies to VP1 of swine pasivirus in humans without evidence of transmission from a pig source.

P. Coursaget, D. Hober, J. Bellalou, 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Simultaneous administration of hepatitis B and yellow fever vaccines

B. Yvonnet, P. Coursaget, V. Deubel, 1986, Journal of medical virology.

Natural killer and dendritic cells collaborate in the immune response induced by the vaccine against uterine cervical cancer

P. Coursaget, P. Delvenne, J. Koch, 2014, European journal of immunology.

Clinician's guide to human papillomavirus immunology: knowns and unknowns.

P. Coursaget, M. Einstein, J. Schiller, 2009, The Lancet. Infectious diseases.

Hepatitis B virus infection in lepromatous and tuberculoid patients from Senegal.

B. Yvonnet, P. Coursaget, J. Languillon, 1989, Acta leprologica.

Risk factors of invasive cervical cancer in Mali.

P. Coursaget, N. Muñoz, S. de Sanjosé, 2002, International journal of epidemiology.

Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys

P. Coursaget, S. Franceschi, N. Muñoz, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Prevalence of Anti-Human Papillomavirus Type 16, 18, 31, and 58 Virus-Like Particles in Women in the General Population and in Prostitutes

P. Coursaget, S. de Sanjosé, C. Meijer, 2001, Journal of Clinical Microbiology.

Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand.

P. Coursaget, S. Franceschi, N. Muñoz, 2003, The Journal of infectious diseases.

Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses

P. Coursaget, N. Christensen, A. Touzé, 2002, Journal of Virology.

Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis

P. Coursaget, E. Granieri, M. Tognon, 2010, Neurological Sciences.

Hepatitis E virus infection in soldiers sent to endemic regions

P. Coursaget, R. Bercion, Y. Buisson, 1994, The Lancet.

Cervical cancer control, priorities and new directions

J. T. Cox, P. Coursaget, F. X. Bosch, 2004, International journal of cancer.

Human papillomaviruses and cancer in Uganda

V. Beral, P. Coursaget, D. Parkin, 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Simultaneous injection of hepatitis B vaccine with BCG and killed poliovirus vaccine.

B. Yvonnet, P. Coursaget, M. Frenkiel, 1992, Vaccine.

Vaccine against hepatitis B — 18 months prevention in a high risk setting

P. Coursaget, P. Bagros, A. Goudeau, 1978, Medical Microbiology and Immunology.

VIRUS-LIKE PARTICLES ASSOCIATED WITH NON-A, NON-B HEPATITIS

P. Coursaget, F. Barin, P. Maupas, 1979, The Lancet.

Hepatitis B virus infection and hepatocellular carcinoma in Senegal: Prevalence and prevention

B. Yvonnet, P. Coursaget, D. Leboulleux, 1993 .

Immune response to hepatitis B vaccination at birth

B. Yvonnet, P. Coursaget, A. Goudeau, 1985 .

Chapter 15: HPV vaccine use in the developing world.

P. Coursaget, F. Cutts, M. Kane, 2006, Vaccine.

Identification of a novel hepatitis E virus in Nigeria.

P. Coursaget, M. Grandadam, B. Innis, 2000, The Journal of general virology.

Characterization of hepatitis E virus (HEV) from Algeria and Chad by partial genome sequence

P. Coursaget, R. Warren, Y. Buisson, 1997, Journal of medical virology.

The epidemiology of conjunctival squamous cell carcinoma in Uganda

V. Beral, P. Coursaget, D. Parkin, 2003, British Journal of Cancer.

African strains of hepatitis E virus that are distinct from Asian strains

P. Coursaget, S. Emerson, R. Purcell, 1997, Journal of medical virology.

Antibody response to preS1 in hepatitis-B-virus-induced liver disease and after immunization.

B. Yvonnet, P. Coursaget, J. Chiron, 1990, Research in virology.

LOW-DOSE HEPATITIS B VACCINE IMMUNISATION IN CHILDREN

B. Yvonnet, P. Coursaget, D. Leboulleux, 1987, The Lancet.

Long-term efficacy of hepatitis B vaccine in infants from an endemic area

B. Yvonnet, P. Coursaget, I. Diop‐Mar, 1986 .

Vaccine against hepatitis B in children: prevention of hepatitis in a pediatric hemodialysis unit.

P. Coursaget, H. Nivet, A. Goudeau, 1982, The International journal of pediatric nephrology.

Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine.

B. Yvonnet, P. Coursaget, J. Chiron, 1992, Vaccine.

Hepatitis B vaccine: immunization of children and newborns in an endemic area (Senegal).

B. Yvonnet, P. Coursaget, A. Goudeau, 1983, Developments in biological standardization.

HPV vaccine use in the developing world

P. Coursaget, F. Cutts, M. Kane, 2006 .

Simultaneous injection of hepatitis B and measles vaccines.

B. Yvonnet, P. Coursaget, J. Chiron, 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Inhibition of cervical cancer cell growth by human papillomavirus virus–like particles packaged with human papillomavirus oncoprotein short hairpin RNAs

P. Coursaget, G. Gaud, P. Sizaret, 2009, Molecular Cancer Therapeutics.

Antibody to hepatitis B core antigen in chronic active hepatitis.

P. Coursaget, C. Degott, P. Bories, 1978, British medical journal.

Hepatitis E and hepatitis C virus infections among French soldiers with non‐A, non‐B hepatitis

P. Coursaget, Y. Buisson, K. Krawczyński, 1993, Journal of medical virology.

Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers.

P. Coursaget, B. Chiang, S. Yeh, 1985, The Journal of infectious diseases.

Merkel cell polyomavirus strains in patients with merkel cell carcinoma.

P. Coursaget, C. Clavel, A. Maruani, 2009 .

Hepatitis B vaccine: clinical trials in high-risk settings in France. (September 1975-September 1982).

P. Coursaget, A. Goudeau, F. Barin, 1983, Developments in biological standardization.

Hepatitis type E in a French population: detection of anti-HEV by a synthetic peptide-based enzyme-linked immunosorbent assay.

P. Coursaget, Y. Buisson, C. Molinié, 1994, Research in virology.

SAFETY OF HEPATITIS-B VACCINES: NO EVIDENCE OF AUTOIMMUNITY

P. Coursaget, D. Doniach, A. Goudeau, 1979, The Lancet.

Hepatitis B vaccine: efficacy in high-risk settings, a two-year study.

P. Coursaget, P. Bagros, A. Goudeau, 1978, Intervirology.

Efficacy of vaccine against hepatitis B; epidemiological data.

P. Coursaget, P. Bagros, A. Goudeau, 1977, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

Merkel cell polyomavirus infection occurs during early childhood and is transmitted between siblings.

P. Coursaget, D. Trégouët, L. Abel, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Trichodysplasia Spinulosa Polyomavirus Infection Occurs during Early Childhood with Intrafamilial Transmission, Especially from Mother to Child.

P. Coursaget, L. Abel, V. Pedergnana, 2017, The Journal of investigative dermatology.

Complexes between HBsAg and IgM in serum of patients with viral hepatitis B

P. Coursaget, A. Couroucé, F. Bouchardeau, 1985 .

Simultaneous administration of hepatitis B and yellow fever vaccines.

B. Yvonnet, P. Coursaget, I. Diop‐Mar, 1986, Developments in biological standardization.

Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys

P. Coursaget, S. Franceschi, N. Muñoz, 2010, Cancer Epidemiology, Biomarkers & Prevention.

EARLY ASYMPTOMATIC HEPATITIS A IN SENEGALESE CHILDREN

P. Coursaget, F. Barin, J. Chotard, 1980, The Lancet.